The accurate prediction of pharmacokinetics (PK) is fundamental to underwriting safety and
efficacy in pediatric clinical trials; age‐dependent PK may be observed with pediatrics …

Drug-drug interactions may cause serious adverse events in the clinical setting, and the
cytochromes P450 are the enzyme system most often implicated in these interactions. …

Understanding the potential for cytochrome P450-mediated drug-drug interactions (DDIs) is
a critical step in the drug discovery process. DDIs of CYP3A4 are of particular importance …

Predicting the magnitude of potential drug-drug interactions is important for underwriting
patient safety in the clinical setting. Substrate-dependent inhibition of cytochrome P450 …

Understanding the potential for cytochrome P450 (P450)-mediated drug-drug interactions is
a critical step in the drug discovery process. Although in vitro studies with CYP3A4, CYP2C9…

Advances in drug interaction screening have resulted in reduced compound attrition rates
due to unfavorable CYP-mediated drug interactions in clinical trials and improved patient …

Understanding the potential for cytochrome P450 (P450)-mediated drug-drug interactions is
a critical part of the drug discovery process. Factors such as nonspecific binding, atypical …

When choosing a recombinant cytochrome P450 (P450) enzyme system for in vitro studies,
it is critical to understand the strengths, limitations, and applicability of the enzyme system to …

The role of C239 as the active-site residue responsible for forming the covalent linkage with
raloxifene during P450 3A4 time-dependent inactivation (TDI) was recently identified. The …

Studies were designed to investigate the possible mechanisms associated with the kinetic
observation of CYP2C9 activation by dapsone and its phase I metabolite, N-hydroxydapsone. …